Insights & Analysis
There’s one constant in healthcare: change. Count on us to break down the trends so you can stay up to date. Follow our take on each piece of this deep, intertwined, and often perplexing industry to find opportunities and practical approaches to move healthcare forward.
The House and Senate are advancing legislative packages aimed at mitigating the crisis.
President Trump is expected to announce a drug pricing plan in the coming weeks; signals from the White House indicate potential alignment around several priority policies.
Avalere examines the effect of foundation-sponsored financial assistance on out-of-pocket costs and federal spending.
MSSP and CMMI demonstrations vary in budgetary impact but generally show quality improvement.
Coordinated information sharing can facilitate the delivery of integrated care to patients using both physical and behavioral health services.
In response to the concern that overprescribing is a driver of the opioid crisis, payers are limiting opioid fills as one solution.
The Centers for Medicare & Medicaid Services released the final Notice of Benefit and Payment Parameters (NBPP) for the 2019 plan year.
In just two years, on March 23, 2020, biologics currently regulated as drugs will transition to being regulated as biologics. Many aspects of how FDA will implement this transition have yet to be established.
Most people are familiar with generic drugs as less costly alternatives to drugs whose patents have expired.
Increasingly, states are taking steps to control prescription drug spending and prices.
On March 6, Avalere experts came together to discuss the latest Medicaid developments.
The findings, published in The Journal of Endocrinology & Metabolism, will guide a pilot study to assess interventions to improve the identification and management of diabetes patients at high risk for hypoglycemia.
On February 9, the Senate voted to pass the Bipartisan Budget Act of 2018, which funds the government through March 23, lifts spending caps for 2 years, and suspends the debt ceiling until March 2019.
In the US, an interchangeability designation by the Food & Drug Administration (FDA) is perceived as the holy grail in biosimilars development by some and yet regarded as irrelevant by others.
Today, the Trump Administration released its budget for fiscal year 2019 (FY 2019).
Avalere experts provide their insights on what the impact of coverage gap discount changes in budget agreement.
Last month, the Centers for Medicare & Medicaid Services (CMS) released a Request for Application (RFA) for the Bundled Payment for Care Improvement (BPCI) Advanced initiative.
Yesterday, the Centers for Medicare & Medicaid Services (CMS) released Part II of the Advance Notice and Call Letter (ANCL), describing the Agency's proposed 2019 payment policies and other policy updates for the upcoming plan year for Medicare Advantage (MA) and Part D plans.
With applications for the new Bundled Payment for Care Improvement (BPCI) Advanced initiative due on March 12, providers have a short window to act.
The shift from volume to value has played a significant role in shaping current payer behavior in the oncology space.